What is Alzamend Neuro Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Alzamend Neuro's interest expense for the
three
months ended in Jan. 2024 was $ -0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.01 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Alzamend Neuro's Operating Income for the
three
months ended in Jan. 2024 was $ -2.66 Mil. Alzamend Neuro's Interest Expense for the
three
months ended in Jan. 2024 was $ -0.00 Mil.
Alzamend Neuro did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Alzamend Neuro Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (NAS:ALZN) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Alzamend Neuro's Interest Expense for the
three
months ended in Jan. 2024 was $-0.00 Mil. Its
Operating Income
for the
three
months ended in Jan. 2024 was $-2.66 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Jan. 2024 was $0.00 Mil.
Alzamend Neuro's Interest Coverage for the quarter that ended in Jan. 2024 is calculated as
| Alzamend Neuro did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Alzamend Neuro (Alzamend Neuro) Business Description
Traded in Other Exchanges
N/A
Address
3480 Peachtree Road NE, Second Floor Suite 103, Atlanta, GA, USA, 30326
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
Executives
| Ault Milton C Iii |
10 percent owner |
11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141 |
| David J Katzoff |
officer: Chief Operating Officer |
201 SHIPYARD WAY, NEWPORT BEACH CA 92663 |
| Stephan Jackman |
director, officer: Chief Executive Officer |
C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
| Lynne Fahey Mcgrath |
director |
28145 CEDAR POINT RD., EASTON MD 21601 |
| Mark Gustafson |
director |
10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9 |
| William B. Horne |
director |
C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626 |
| Henry Carl Nisser |
director, officer: Exec VP and General Counsel |
100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017 |
| Kenneth S Cragun |
officer: SVP of Finance |
3775 CHIPPEWA CIRCLE, CORONA CA 92881 |
| Jeffrey Oram |
director |
15 ORCHARD STREET, MENDHAM NJ 07945 |
| Escalona Lien |
officer: Chief Financial Officer |
C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
| Andrew H. Woo |
director |
2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404 |
Alzamend Neuro (Alzamend Neuro) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALZN has been successfully added to your 